Verseon Corporation Verseon granted US patents for its inhibitors
January 04 2017 - 1:00AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
04 January 2017
Press release January 4, 2017
Verseon Corporation
("Verseon" or the "Company")
Verseon granted US patents covering its novel serine protease
inhibitors
Strengthens intellectual property protection for Verseon's drug
programs
FREMONT, Calif.-The United States Patent and Trademark Office
has granted Verseon, a technology-based pharmaceutical company, US
Patents No. 9,533,967 and 9,533,970, which cover various aspects of
multiple families of compounds that were designed by the Company
for its drug programs. Verseon had previously obtained patent
protection in China, New Zealand, Israel, and Australia related to
the subject matter of US Patent 9,533,967.
Among other aspects, the patents demonstrate the novelty and
nonobviousness of compounds related to Verseon's anticoagulant
program. In preclinical studies, the Company's oral direct thrombin
inhibitors have demonstrated efficacy comparable to current
anticoagulants along with reduced bleeding risk and are expected to
enter clinical trials in 2017.
"The newly issued patents are an important milestone in our
ongoing effort to strengthen the intellectual property protection
for our drug programs in key markets. We expect to receive further
patents in the near future," said David Kita, co-founder and Vice
President of Research and Development at Verseon. "Our
anticoagulant candidates have the potential to change the standard
of care for millions of patients with thrombosis-related
disorders."
About Verseon's Anticoagulant Program
Verseon's potent, highly selective, oral direct thrombin
inhibitors act through reversible covalent inhibition, a unique
mode of action. Preclinical studies show that Verseon's inhibitors
act as effective anticoagulants in multiple efficacy studies, but
do not disrupt platelet function. This unique feature could explain
their observed low bleeding risk. One of Verseon's lead candidates
furthermore shows very low renal clearance, a highly desirable
property for patients with impaired renal function.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Arthur Shmurun / Amy Thai 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Sophie +44 (0) 20
Cowles 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFLFLDIVIID
(END) Dow Jones Newswires
January 04, 2017 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024